What A TRT Blood Test Measures And When To Retest

A TRT blood test is a monitoring panel that checks how testosterone replacement therapy is affecting hormone levels, red blood cell production, liver function, and kidney health. It typically includes total and free testosterone, estradiol (ultrasensitive), a complete blood count (CBC) with differential, and a comprehensive metabolic panel (CMP). This panel does not diagnose low testosterone. It is a safety and dosing check for patients already on treatment.

Most patients here either have labs coming due, recently changed their dose, or noticed something is off. Fatigue returned. Libido dropped. The TRT blood test helps the provider evaluate whether the problem is the dose, a side effect, or something unrelated to testosterone.

The Endocrine Society's 2018 clinical practice guideline recommends monitoring at three to six months after starting TRT, then annually thereafter (Bhasin et al., 2018). Yet a 2026 analysis presented at ENDO found that only 12% of men prescribed testosterone had guideline-concordant testing (Sinha & Papaleontiou, 2026). That leaves 88% of patients with incomplete data about how their therapy is actually performing.

Why Patients on TRT Need Regular Blood Work

This panel does not diagnose testosterone deficiency. Diagnosis requires two separate morning blood draws showing total testosterone consistently below 300 ng/dL, plus symptoms of hypogonadism (Mulhall et al., 2018). The Endocrine Society further recommends fasting draws (Bhasin et al., 2018). The TRT blood test comes after diagnosis and treatment have already started.

Without regular monitoring, problems build quietly. Hematocrit (red blood cell concentration) can climb to levels associated with increased blood viscosity and potential cardiovascular risk. A 2025 retrospective study of 247 men on TRT found that 23% reached a hematocrit above 50%, and 5% exceeded the 54% threshold where clinical guidelines recommend intervention (Neidhart et al., 2025).

Estradiol can also rise without obvious symptoms at first. Testosterone converts to estradiol through the aromatase enzyme, and when levels climb too high, patients may experience fluid retention, breast tissue changes, or mood instability. Monitoring through estradiol-sensitive testing can help identify these shifts early.

The FDA updated testosterone labeling in February 2025, removing the previous boxed cardiovascular warning after TRAVERSE trial results and adding a class-wide blood pressure warning based on postmarket ambulatory blood pressure monitoring (ABPM) studies (FDA, 2025).

What Does a TRT Blood Test Measure?

The standard panel covers four marker categories. Providers may add tests based on individual risk, but these four form the baseline.

Testosterone (total and free). Total testosterone measures all testosterone in the blood. Free testosterone measures only the unbound portion available to tissues. When total T looks normal but symptoms persist, high SHBG (sex hormone-binding globulin) may be binding most of the available hormone. The Endocrine Society recommends measuring free testosterone by equilibrium dialysis or a calculated formula when total T is near the lower limit or when SHBG-altering conditions are present (Bhasin et al., 2018). The harmonized reference range for healthy young men is 264-916 ng/dL (Travison et al., 2017).

Estradiol, ultrasensitive. This measures estradiol using the LC-MS/MS method rather than standard immunoassay. Standard assays built for female reference ranges lack precision in the male range (typically 10-40 pg/mL). Dose adjustments, body fat changes, and aromatase activity all shift the testosterone-to-estradiol ratio.

CBC with differential. This tracks red blood cells, white blood cells, hemoglobin, and hematocrit. Hematocrit is the most watched marker. Multiple clinical guidelines flag a level above 54% as requiring dose reduction or therapeutic phlebotomy (Bhasin et al., 2018; Mulhall et al., 2018). Erythrocytosis is the most common laboratory adverse effect of testosterone therapy.

Comprehensive metabolic panel (CMP). This checks liver enzymes, kidney function markers (BUN, creatinine), fasting glucose, and electrolytes. Oral testosterone formulations carry the most liver-related monitoring needs.

One note on biotin: supplements containing biotin (vitamin B7), common in hair, skin, and nail products, can interfere with hormone immunoassays. The FDA flagged this in a 2017 safety communication after adverse event reports, including one death from a falsely low troponin result. Patients should discuss biotin use with their provider and generally stop biotin-containing supplements at least 72 hours before any blood draw.

When Should Patients Retest on TRT?

Timing depends on where someone is in treatment. The general framework from the Endocrine Society guideline (Bhasin et al., 2018):

• Starting TRT: First retest at three months, second at six months

• Stable TRT: Annually, once no symptoms or dose changes are present

• After any dose adjustment: Retest three months after each change

Testing too early (before four to six weeks) may not reflect steady-state levels. Testing too late means months of unverified dosing without data.

Draw timing relative to injection schedule also matters. For patients on testosterone cypionate or enanthate, blood drawn at trough (just before the next injection) gives the lowest reading. Blood drawn 24-48 hours post-injection shows near-peak levels. Most guidelines recommend trough draws, but the key is keeping timing consistent across tests.

For transdermal gel or cream users, blood should be drawn two to four hours after application for peak, or immediately before the next application for trough.

How to Order and Prepare for a TRT Blood Test

Patients can get this panel through their prescribing provider, a telehealth provider, or a CLIA-certified laboratory. Some telehealth providers include periodic lab orders as part of treatment. Others require patients to arrange lab work independently. Consumer-ordered labs are generally not included in standard insurance or employer reporting, though patients should verify their lab provider's specific privacy policies.

The prescribing provider should still interpret the results. A hematocrit of 51% means different things at sea level versus 5,000 feet elevation. Numbers without clinical context can lead to self-adjusted doses, one of the more common mistakes between appointments.

Fasting: At least eight hours. Water is fine. Skip food, juice, coffee, and anything caloric. The CMP requires fasting for accurate glucose readings.

Timing: Between 7 and 10 a.m. Testosterone follows a circadian rhythm, peaking in early morning and dropping through the afternoon. A draw at 3 p.m. can show levels 20-25% lower than the same patient's 8 a.m. reading. Both the Endocrine Society and AUA guidelines specify early-morning draws.

Biotin: Stop any supplement containing biotin at least 72 hours before the draw.

Patients should also inform their provider about all medications. Opioids, glucocorticoids, and certain anticonvulsants affect testosterone levels independent of TRT and can confuse the clinical picture.

What Happens During and After the Draw?

A technician draws blood from a vein in the arm. Results are typically available within one to three business days. Patients should review results with their prescribing clinician rather than interpreting individual numbers in isolation.

How to Read TRT Blood Test Results

Providers read results across all four marker categories together, alongside symptoms and treatment history. Therapeutic targets on TRT are narrower than general population ranges. Many clinicians target a total testosterone range of roughly 400-700 ng/dL at trough, though individual targets depend on symptom response and side effect profile.

A single out-of-range result doesn't automatically call for a dose change. Draw timing, hydration, recent illness, and medication interactions all affect a single snapshot. Providers typically confirm concerning findings with a repeat draw before adjusting treatment.

When Results Fall Within Range

In-range results across all four categories suggest therapy is performing as expected at the current dose, though clinical assessment remains important for effects not captured by lab work alone. But "in range" doesn't mean symptoms have resolved. If fatigue persists despite normal total testosterone, providers may examine free testosterone and SHBG, thyroid function, or sleep quality.

Routine monitoring continues on schedule. Annually is standard once levels are stable.

What Do Out-of-Range Results Mean?

Specific findings trigger specific responses:

High hematocrit (above 54%). The most common TRT-related lab abnormality. Per the Endocrine Society guideline, the provider may lower the dose, change injection frequency, switch to a transdermal formulation, or recommend therapeutic phlebotomy (Bhasin et al., 2018). Patients should not stop therapy on their own.

High estradiol. May reflect increased aromatase conversion. The provider may reduce testosterone dose, address contributing factors like body fat percentage, or consider other individualized interventions. Symptoms can include fluid retention, mood changes, and breast tissue sensitivity.

Low free testosterone with normal total testosterone. High SHBG is the usual explanation. SHBG rises with age, liver conditions, thyroid dysfunction, and certain medications. The provider may adjust delivery method or investigate the underlying cause.

Abnormal CMP values. Elevated liver enzymes, kidney function changes, or blood sugar shifts may prompt a review of the testosterone formulation, other medications, alcohol intake, or broader metabolic screening.

Blood pressure elevation. Following the FDA's 2025 label update, blood pressure monitoring is standard for TRT patients. The TRAVERSE trial (5,246 men with hypogonadism and cardiovascular risk factors) showed testosterone was noninferior to placebo for major cardiovascular events (7.0% vs. 7.3%), but secondary findings included higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism (Lincoff et al., 2023). These secondary findings were not corrected for multiple comparisons and should be interpreted with caution.

Patients working with a clinician experienced in TRT should discuss all out-of-range findings before making any changes to their protocol.

The Bottom Line on TRT Blood Tests

A TRT blood test is not optional lab work. It is one of the most important tools to confirm that therapy is working without causing problems that haven't surfaced yet. The 88% of patients who skip guideline-concordant monitoring are taking a medication that affects red blood cell production, estrogen metabolism, liver function, and cardiovascular risk with incomplete visibility. Patients who test on schedule, fast before the draw, and arrive before 10 a.m. give their provider the most accurate data to guide treatment decisions. The TRT blood test doesn't change the treatment. It tells the provider whether the treatment needs to change.

Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.

FAQs

How often should TRT blood work be done?

The Endocrine Society recommends testing at three months and six months after starting testosterone therapy, then annually once levels are stable. Any dose change should trigger a retest three months later. A 2026 study found only 12% of men on TRT received guideline-concordant testing, which means most patients are monitored less frequently than clinical guidelines recommend.

What is a normal testosterone level while on TRT?

The harmonized reference range for total testosterone in healthy young men is 264-916 ng/dL. On TRT, most clinicians target 400-700 ng/dL measured at trough (before the next dose). Individual targets vary based on symptom response, side effects, and the delivery method used. A number that looks "normal" on paper can still leave a patient symptomatic if free testosterone is low due to high SHBG.

Does a TRT blood test check estrogen levels?

Yes. The panel includes estradiol measured by the ultrasensitive LC-MS/MS method, which is more accurate for male-range values (10-40 pg/mL) than standard immunoassay. Monitoring estradiol matters because testosterone converts to estradiol through aromatase. Elevated estradiol can cause fluid retention, mood changes, and breast tissue sensitivity.

Can biotin supplements affect TRT blood test results?

Biotin (vitamin B7) can interfere with immunoassay-based hormone tests, producing falsely high or falsely low readings depending on the assay design. The FDA issued a safety communication about this risk in 2017 after adverse event reports, including one death from a falsely low troponin result. Patients should stop biotin at least 72 hours before any blood draw.

What time of day should a TRT blood test be scheduled?

Between 7 and 10 a.m. Testosterone follows a circadian rhythm with peak levels in early morning. An afternoon draw can show levels 20-25% lower than the same patient's morning value. Both the Endocrine Society and AUA specify early-morning draws, and the Endocrine Society recommends fasting for accuracy.

Does hematocrit always increase on TRT?

Not always, but it is the most common lab-related side effect of testosterone therapy. A 2025 retrospective study found that 23% of men on TRT developed a hematocrit above 50%, and 5% crossed the 54% threshold where guidelines recommend dose adjustment or therapeutic phlebotomy. Injectable testosterone raises hematocrit more than transdermal formulations.

Should LH and FSH be checked on a TRT monitoring panel?

LH and FSH are not part of the standard TRT monitoring panel because exogenous testosterone suppresses both hormones. They are diagnostic markers used before starting therapy to distinguish primary hypogonadism (testicular failure, elevated LH/FSH) from secondary hypogonadism (pituitary issue, low LH/FSH). Once on TRT, LH and FSH testing is most relevant if fertility preservation is a concern, since suppressed gonadotropins indicate reduced sperm production.

References

• J Clin Endocrinol Metab. 2018;103(5):1715–1744

• J Urol. 2018;200(2):423–432

• N Engl J Med. 2023;389(2):145–158

• Front Endocrinol. 2025;15:1496906

• J Clin Endocrinol Metab. 2017;102(4):1161–1173